"Proto-Oncogenes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Normal cellular genes homologous to viral oncogenes. The products of proto-oncogenes are important regulators of biological processes and appear to be involved in the events that serve to maintain the ordered procession through the cell cycle. Proto-oncogenes have names of the form c-onc.
| Descriptor ID |
D011519
|
| MeSH Number(s) |
G05.360.340.024.340.375.500.791
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogenes".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogenes".
- Proto-Oncogenes
- Genes, abl
- Genes, bcl-1
- Genes, bcl-2
- Genes, erbA
- Genes, erbB
- Genes, fms
- Genes, fos
- Genes, jun
- Genes, mos
- Genes, myb
- Genes, myc
- Genes, ras
- Genes, rel
- Genes, sis
- Genes, src
This graph shows the total number of publications written about "Proto-Oncogenes" by people in this website by year, and whether "Proto-Oncogenes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 5 | 2 | 7 |
| 1995 | 6 | 3 | 9 |
| 1996 | 2 | 4 | 6 |
| 1997 | 1 | 2 | 3 |
| 1998 | 4 | 4 | 8 |
| 1999 | 1 | 1 | 2 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 2 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 4 | 0 | 4 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 2 | 3 |
| 2007 | 4 | 1 | 5 |
| 2008 | 0 | 2 | 2 |
| 2010 | 2 | 1 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 1 | 2 |
| 2021 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogenes" by people in Profiles.
-
Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy. J Exp Clin Cancer Res. 2024 Mar 06; 43(1):70.
-
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia. 2024 03; 38(3):545-556.
-
Precision therapy for RET-altered cancers with RET inhibitors. Trends Cancer. 2021 12; 7(12):1074-1088.
-
Context-dependent functions of KLF4 in cancers: Could alternative splicing isoforms be the key? Cancer Lett. 2018 12 01; 438:10-16.
-
3' UTR shortening represses tumor-suppressor genes in trans by disrupting ceRNA crosstalk. Nat Genet. 2018 06; 50(6):783-789.
-
Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report. Br J Haematol. 2017 05; 177(4):601-611.
-
High-Fat Diet-Induced Complement Activation Mediates Intestinal Inflammation and Neoplasia, Independent of Obesity. Mol Cancer Res. 2016 10; 14(10):953-965.
-
Functional features of EVI1 and EVI1?324 isoforms of MECOM gene in genome-wide transcription regulation and oncogenicity. Oncogene. 2016 05 05; 35(18):2311-21.
-
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014 May 21; 311(19):1998-2006.
-
Mice carrying a hypomorphic Evi1 allele are embryonic viable but exhibit severe congenital heart defects. PLoS One. 2014; 9(2):e89397.